| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8652822 | The Annals of Thoracic Surgery | 2018 | 8 Pages |
Abstract
The mechanism for foretinib growth inhibition in MET-amplified EAC tumor cells is demonstrated. The interplay of dual MET/HER2 overexpression in the AKT and ERK pathways for esophageal cancer is described. Therefore, combination therapy could be a novel strategy for EAC with amplification of both MET and HER2.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Alexei A. PhD, Bingliang MD, PhD, Tej K. PhD, Dipen M. MD, Stephen G. MD, Wayne L. MD,